Cellectis Exits Two CAR-T Programs, Shifts Focus to Gene Editing for Lipid Disorders
Cellectis (CLLS) has announced a strategic shift on September 14, exiting the internal development of its two CAR-T therapies—lasme-cel and eti-cel—and seeking partners instead. The company will now prioritize preclinical programs targeting severe lipid disorders using in vivo gene editing technologies: HEAL-101 for hypertriglyceridemia and HEAL-201 for hypercholesterolemia, both delivered via lipid nanoparticles. The decision reflects a capital allocation strategy driven by reduced patient populations due to improved frontline cancer treatments and slower enrollment. Cellectis aims to extend its cash runway through 2028 while preserving existing cell therapy partnerships. However, the new programs are still preclinical with no commercialization timeline yet established. While the pivot could reduce development costs for smaller markets, it also represents a significant clinical reset from active trials in CAR-T therapies. The success of HEAL-101 and HEAL-201 will depend on demonstrating durable efficacy and safety in human trials starting as early as 2027.
Tickers: $CLLS
Topics: CAR-T therapy gene editing lipid disorders pipeline strategy